Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Portfolio Pulse from Chris Katje
Ark Innovation ETF (ARKK) and Ark Genomic Revolution ETF (ARKG), both managed by Cathie Wood's Ark Funds, celebrate their 10th anniversaries. Despite strong growth in the past, both ETFs have underperformed the S&P 500 in recent years. ARKK focuses on disruptive innovation, while ARKG targets the genomics revolution. The funds' active management style and focus on long-term growth mean returns can take years to materialize.
October 31, 2024 | 7:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SPY, the SPDR S&P 500 ETF Trust, has outperformed both ARKK and ARKG over the past 10 years. It remains a benchmark for comparing ETF performance.
SPY has consistently outperformed ARKK and ARKG, highlighting its stability and broad market exposure. It serves as a benchmark for ETF performance.
CONFIDENCE 95
IMPORTANCE 70
RELEVANCE 50
NEUTRAL IMPACT
ARKG, Ark Genomic Revolution ETF, also celebrates its 10th anniversary. It has underperformed the S&P 500, focusing on genomics and related sectors. The fund's active management and long-term growth strategy may lead to delayed returns.
ARKG has underperformed the S&P 500 since inception. Its focus on genomics and active management strategy suggest potential for future growth, but short-term performance may be limited.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
ARKK, Ark Innovation ETF, celebrates its 10th anniversary. Despite past strong growth, it has underperformed the S&P 500 in recent years. The fund focuses on disruptive innovation and is actively managed, which can lead to variable returns.
ARKK has shown significant growth since inception but has underperformed the S&P 500 recently. Its focus on disruptive innovation suggests potential for future growth, but short-term performance may remain variable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100